Aptamers as new promising entities
for therapeutics: our experience
from the neurological diseases
Macarena Hernández-Jiménez, Fernando de Castro*
Neurovascular Research Unit, Pharmacology and
Toxicology Department, Complutense University, Madrid,
Spain (Hernández-Jiménez M)
AptaTargets S.L., Avda. Cardenal Herrera Oria, Madrid,
Spain (Hernández-Jiménez M)Instituto de Investigación Hospital 12 de Octubre, Madrid,
Spain (Hernández-Jiménez M)
Instituto Cajal-CSIC, Madrid, Spain (de Castro F)
Online:2025-12-15
Published:2025-03-15
Contact:
Fernando de Castro, MD, PhD, fdecastro@cajal.csic.es.
Supported by:
Macarena Hernández-Jiménez is the scientific advisor
of AptaTargets S.L. No conflicts of interest exist between
AptaTargets S.L. and publication of this paper.
The research group directed by Fernando de Castro
developed part of its research from 2018 to 2023 under
contracts #20184174 and #Apta_misiones_009 signed
with Apta Targets, S.L.
Macarena Hernández-Jiménez, Fernando de Castro. Aptamers as new promising entities
for therapeutics: our experience
from the neurological diseases[J]. Neural Regeneration Research, 2025, 20(12): 3523-3524.